Literature DB >> 24595511

Mindfulness-based cognitive therapy for recurrent depression: A translational research study with 2-year follow-up.

Graham N Meadows1, Frances Shawyer2, Joanne C Enticott3, Annette L Graham2, Fiona Judd4, Paul R Martin5, Leon Piterman6, Zindel Segal7.   

Abstract

OBJECTIVE: While mindfulness-based cognitive therapy (MBCT) has demonstrated efficacy in reducing depressive relapse/recurrence over 12-18 months, questions remain around effectiveness, longer-term outcomes, and suitability in combination with medication. The aim of this study was to investigate within a pragmatic study design the effectiveness of MBCT on depressive relapse/recurrence over 2 years of follow-up.
METHOD: This was a prospective, multi-site, single-blind trial based in Melbourne and the regional city of Geelong, Australia. Non-depressed adults with a history of three or more episodes of depression were randomised to MBCT + depression relapse active monitoring (DRAM) (n=101) or control (DRAM alone) (n=102). Randomisation was stratified by medication (prescribed antidepressants and/or mood stabilisers: yes/no), site of usual care (primary or specialist), diagnosis (bipolar disorder: yes/no) and sex. Relapse/recurrence of major depression was assessed over 2 years using the Composite International Diagnostic Interview 2.1.
RESULTS: The average number of days with major depression was 65 for MBCT participants and 112 for controls, significant with repeated-measures ANOVA (F(1, 164)=4.56, p=0.03). Proportionally fewer MBCT participants relapsed in both year 1 and year 2 compared to controls (odds ratio 0.45, p<0.05). Kaplan-Meier survival analysis for time to first depressive episode was non-significant, although trends favouring the MBCT group were suggested. Subgroup analyses supported the effectiveness of MBCT for people receiving usual care in a specialist setting and for people taking antidepressant/mood stabiliser medication.
CONCLUSIONS: This work in a pragmatic design with an active control condition supports the effectiveness of MBCT in something closer to implementation in routine practice than has been studied hitherto. As expected in this translational research design, observed effects were less strong than in some previous efficacy studies but appreciable and significant differences in outcome were detected. MBCT is most clearly demonstrated as effective for people receiving specialist care and seems to work well combined with antidepressants. © The Royal Australian and New Zealand College of Psychiatrists 2014.

Entities:  

Keywords:  Depression; mindfulness-based cognitive therapy; randomised controlled trial; relapse prevention; subgroup analyses

Mesh:

Year:  2014        PMID: 24595511     DOI: 10.1177/0004867414525841

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  13 in total

1.  Relapse prevention in major depressive disorder: Mindfulness-based cognitive therapy versus an active control condition.

Authors:  Amanda J Shallcross; James J Gross; Pallavi D Visvanathan; Niketa Kumar; Amy Palfrey; Brett Q Ford; Sona Dimidjian; Stephen Shirk; Jill Holm-Denoma; Kari M Goode; Erica Cox; William Chaplin; Iris B Mauss
Journal:  J Consult Clin Psychol       Date:  2015-08-10

2.  Mindfulness-Based Interventions in Psychiatry.

Authors:  Benjamin G Shapero; Jonathan Greenberg; Paola Pedrelli; Marasha de Jong; Gaelle Desbordes
Journal:  Focus (Am Psychiatr Publ)       Date:  2018-01-24

3.  Relapse/Recurrence Prevention in Major Depressive Disorder: 26-Month Follow-Up of Mindfulness-Based Cognitive Therapy Versus an Active Control.

Authors:  Amanda J Shallcross; Emily C Willroth; Aaron Fisher; Sona Dimidjian; James J Gross; Pallavi D Visvanathan; Iris B Mauss
Journal:  Behav Ther       Date:  2018-02-08

Review 4.  Mindfulness-based cognitive therapy for depression: trends and developments.

Authors:  Meagan B MacKenzie; Nancy L Kocovski
Journal:  Psychol Res Behav Manag       Date:  2016-05-19

5.  Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with Chronic Migraine: an effectiveness trial with a one-year follow-up.

Authors:  Licia Grazzi; Emanuela Sansone; Alberto Raggi; Domenico D'Amico; Andrea De Giorgio; Matilde Leonardi; Laura De Torres; Francisco Salgado-García; Frank Andrasik
Journal:  J Headache Pain       Date:  2017-02-04       Impact factor: 7.277

6.  The Impact of Treatments for Depression on the Dynamic Network Structure of Mental States: Two Randomized Controlled Trials.

Authors:  Evelien Snippe; Wolfgang Viechtbauer; Nicole Geschwind; Annelie Klippel; Peter de Jonge; Marieke Wichers
Journal:  Sci Rep       Date:  2017-04-20       Impact factor: 4.379

Review 7.  Mindfulness-based cognitive therapy in patients with depression: current perspectives.

Authors:  Meagan B MacKenzie; Kayleigh A Abbott; Nancy L Kocovski
Journal:  Neuropsychiatr Dis Treat       Date:  2018-06-18       Impact factor: 2.570

8.  Efficacy of Mindfulness-Based Cognitive Therapy in Prevention of Depressive Relapse: An Individual Patient Data Meta-analysis From Randomized Trials.

Authors:  Willem Kuyken; Fiona C Warren; Rod S Taylor; Ben Whalley; Catherine Crane; Guido Bondolfi; Rachel Hayes; Marloes Huijbers; Helen Ma; Susanne Schweizer; Zindel Segal; Anne Speckens; John D Teasdale; Kees Van Heeringen; Mark Williams; Sarah Byford; Richard Byng; Tim Dalgleish
Journal:  JAMA Psychiatry       Date:  2016-06-01       Impact factor: 21.596

9.  Psychotherapy of mood disorders.

Authors:  Angelo Picardi; Paola Gaetano
Journal:  Clin Pract Epidemiol Ment Health       Date:  2014-11-26

10.  Web-based intervention to improve quality of life in late stage bipolar disorder (ORBIT): randomised controlled trial protocol.

Authors:  Kathryn Fletcher; Fiona Foley; Neil Thomas; Erin Michalak; Lesley Berk; Michael Berk; Steve Bowe; Sue Cotton; Lidia Engel; Sheri L Johnson; Steven Jones; Michael Kyrios; Sara Lapsley; Cathrine Mihalopoulos; Tania Perich; Greg Murray
Journal:  BMC Psychiatry       Date:  2018-07-13       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.